Dr. Hidehito Horinouchi, MD, PhD

Claim this profile
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
1 reported clinical trial
3 drugs studied

Area of expertise

1Non-Small Cell Lung Cancer
Hidehito Horinouchi, MD, PhD has run 1 trial for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
ALK negative
EGFR negative
2Lung Cancer
Hidehito Horinouchi, MD, PhD has run 1 trial for Lung Cancer. Some of their research focus areas include:
Stage III
ALK negative
EGFR negative

Clinical Trials Hidehito Horinouchi, MD, PhD is currently running

Image of trial facility.

Immunotherapy Combo

for Lung Cancer

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Recruiting1 award Phase 310 criteria

More about Hidehito Horinouchi, MD, PhD

Clinical Trial Related2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Hidehito Horinouchi, MD, PhD has experience with
  • Domvanalimab
  • Durvalumab
  • Placebo
Breakdown of trials Hidehito Horinouchi, MD, PhD has run
Non-Small Cell Lung Cancer
Lung Cancer

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hidehito Horinouchi, MD, PhD specialize in?
Hidehito Horinouchi, MD, PhD focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage III patients, or patients who are ALK negative.
Is Hidehito Horinouchi, MD, PhD currently recruiting for clinical trials?
Yes, Hidehito Horinouchi, MD, PhD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Hidehito Horinouchi, MD, PhD has studied deeply?
Yes, Hidehito Horinouchi, MD, PhD has studied treatments such as Domvanalimab, Durvalumab, Placebo.
What is the best way to schedule an appointment with Hidehito Horinouchi, MD, PhD?
Apply for one of the trials that Hidehito Horinouchi, MD, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top